New Psychoactive Substances (NPS) Laws in Poland: Designer Drugs Explained

New Psychoactive Substances (NPS) Laws in Poland: Designer Drugs Explained

New psychoactive substances (NPS) are natural or synthetic compounds designed to mimic the effects of controlled drugs (such as cannabis, amphetamines, MDMA, or LSD) while attempting to avoid classic drug schedules. In everyday language they are often called “designer drugs” or “legal highs”. In Poland, the key practical point is that many NPS are treated as illegal under drug laws, and even where a substance is not yet listed as a narcotic/psychotropic drug, placing it on the market or supplying it may still trigger administrative sanctions under the NPS regime depending on the classification and the way it is marketed or supplied.

Designer drugs Poland law – why businesses and individuals should care

NPS cases rarely stay “small”. Law enforcement typically treats them as part of organized distribution networks, online sales, or cross-border supply chains. For companies, NPS risk is not limited to obvious industries (e-commerce, logistics, retail). Exposure can arise through:

• workplace incidents and internal investigations (employee possession, intoxication, accidents),
• import, courier, warehousing and “unknown powder” events,
• online listings, marketplaces and payment processing flags,
• reputational fallout and media interest when allegations involve “legal highs”.

From a compliance perspective, the main challenge is uncertainty: chemical variants change fast, while regulatory updates and forensic identification take time. That gap creates enforcement risk during inspections, searches, or seizures, even when a product is presented as “not for human consumption”.

NPS Poland – the legal framework (criminal and administrative)

Polish law distinguishes between classic controlled substances and “new psychoactive substances”. The core acts are:

• Act of 29 July 2005 on Counteracting Drug Addiction – governs narcotic drugs, psychotropic substances and also introduces the legal regime for NPS [1].
• Act of 14 March 1985 on the State Sanitary Inspection – provides the enforcement toolkit used by sanitary authorities in NPS cases (inspections, administrative measures) [2].

Controlled drugs vs. NPS: what changes in practice

When a substance is classified as a narcotic drug or psychotropic substance under the schedules to the 2005 Act, criminal liability typically focuses on possession, supply, manufacture, import/export and facilitation – with penalties depending on quantity and role in distribution [1].

For NPS, Poland also uses an administrative control model aimed at cutting off “legal highs” retail and online trade. In practice, this may involve decisions to withdraw products from the market, secure stock, and impose administrative fines, and in certain situations criminal proceedings may arise as well (in particular if the substance is actually a scheduled narcotic/psychotropic substance).

Synthetic drugs regulation – how substances become illegal

Regulatory classification depends on whether the compound is placed on statutory lists (schedules) and how it is defined. Updates typically occur through legislative or regulatory amendments linked to the 2005 Act [1].

In operational terms, the “illegality” question is rarely settled by product labels or online descriptions. The decisive elements are:

• laboratory identification of the active compound,
• its current legal status (scheduled drug or NPS under applicable lists),
• evidence of intended use, marketing, packaging, dosage form and distribution patterns.

Legal highs ban – typical enforcement scenarios

“Legal highs” enforcement in Poland often follows recurring patterns:

1. Retail or warehouse inspection – Sanitary authorities secure products suspected to be NPS; parallel police actions may follow if scheduled drugs are suspected.
2. Postal and courier interception – seizures triggered by packaging, declared contents, prior intelligence or chemical screening.
3. Online sales and social media – evidence secured from platforms, messages, payment trails, shipment data; these matters frequently overlap with cyber investigations.
4. Hospital or intoxication incident – a health event starts the chain: toxicology, source tracing, searches and financial analysis.

When the matter involves online ordering, encrypted communications, or digital evidence, early handling of devices and accounts becomes critical. Issues such as the scope and legal basis of searches/seizures, documentation, and chain of custody can materially affect the evidentiary position.

Criminal exposure: what can be investigated and who is at risk

Depending on the factual situation and chemical classification, proceedings may involve suspected offenses under the Act on Counteracting Drug Addiction (for example, possession, supply, manufacture, import/export) and related offenses such as participation in organized crime, money laundering, or document fraud. The legal qualification is case-specific and may change after expert opinions are produced [1].

Risk groups commonly include:

• owners and managers of businesses linked to distribution channels,
• employees handling packages or stock without clear procedures,
• individuals ordering NPS online and sharing them socially,
• IT and e-commerce operators where listings and payment flows are traced.

Key defense and risk-management points in NPS cases

Effective case handling usually requires combining criminal defense with evidence and compliance work. Typical priorities include:

• Immediate verification of classification – whether the seized substance is a scheduled drug or an NPS, and under which list and date regime [1].
• Evidence integrity – how the substance was secured, stored, and sampled; whether laboratory methodology and documentation can be tested.
• Intent and role – whether the evidence supports personal use, incidental handling, or commercial distribution.
• Digital footprint – orders, chats, wallet transfers, platform data, IP logs; this often decides scale and “professional” character.
• Corporate safeguards – internal policies on unknown substances, parcel handling, incident reporting, training, and cooperation protocols with authorities.

For background on how drug-related cases are approached in Poland, KKZ maintains practical materials on drug offences and typical legal consequences, including defense angles and procedural steps: drug offences and drug-related offenses – consequences and defense strategies. Where NPS distribution is tied to online channels, cybercrime experience is often relevant: cybercrime.

Practical guidance for companies: prevention, incident response, documentation

Companies most exposed to accidental involvement (logistics, warehousing, marketplaces, retail, hospitality) should treat NPS as a crisis-management risk. Useful controls include:

• clear “unknown substance” procedures (do not test internally, isolate area, document, escalate),
• training for frontline staff on red flags and safe handling,
• vendor and customer due diligence for high-risk categories,
• records retention for shipments, returns, and customer communications,
• legal review of cooperation with authorities and employee interviews to protect procedural rights.

These measures reduce operational disruption and help show that management exercised due diligence if a case escalates.

This is informational material, not legal advice. The legal assessment depends on the substance, the date of the alleged conduct, the evidence (including lab opinions) and the exact role attributed to a person or business.

If a case involves criminal allegations, including sensitive matters such as sexual offense investigations raised alongside substance-related incidents, it is often necessary to secure a structured legal assessment early. To discuss possible steps and obtain an initial evaluation, contact a lawyer via https://criminallawpoland.com/contact/.

FAQ: New Psychoactive Substances (NPS) Laws in Poland

What are “designer drugs” under Polish law?

“Designer drugs” is not a strict legal category. In practice it refers to NPS or newly modified compounds intended to mimic controlled drugs. Legal consequences in Poland depend on whether the compound is scheduled as a narcotic/psychotropic substance or treated as an NPS under the Act on Counteracting Drug Addiction [1].

Is selling “legal highs” illegal in Poland?

Selling products containing NPS may trigger administrative enforcement and, depending on the compound and evidence, also criminal proceedings (in particular if the substance is in fact a scheduled narcotic/psychotropic substance). Labels such as “collector’s item” do not decide legality; chemical composition and the factual manner of supply are decisive [1].

Can a person be prosecuted if the substance was not clearly listed at the time?

It depends on the date of the act, the then-applicable schedules and classification rules, and whether the substance falls within an existing definition or list. The legal qualification in NPS matters often changes after expert chemical opinions are obtained [1].

How do authorities prove an NPS case?

Typically through seizure documentation, laboratory analysis, witness evidence, digital data (orders, messages, payments), shipment trails and sometimes surveillance. In online cases, platform and device evidence can be central.

What should a company do if suspected NPS are found on premises?

Secure the area, limit access, document what was found (time, place, persons present), and avoid internal testing or handling beyond safety needs. Legal support helps manage employee interviews, evidence preservation, and communications with authorities in a way that protects the business and management.

Are NPS cases connected with cybercrime investigations?

Frequently yes. Online sales, encrypted messaging, and digital payments commonly appear in NPS matters, creating overlap with cybercrime evidence, device searches, and data retention issues.

Bibliography

1. Act of 29 July 2005 on Counteracting Drug Addiction (Poland) – consolidated text available via ISAP: https://isap.sejm.gov.pl/
2. Act of 14 March 1985 on the State Sanitary Inspection (Poland) – consolidated text available via ISAP: https://isap.sejm.gov.pl/